Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199.SS)
CNY 19.25
(-3.12%)
CNY 19.25
(-3.12%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1 Billion CNY | 14.71% |
| 2022 | 876.46 Million CNY | 8.38% |
| 2021 | 808.69 Million CNY | 12.62% |
| 2020 | 718.05 Million CNY | -11.26% |
| 2019 | 809.13 Million CNY | 34.0% |
| 2018 | 603.81 Million CNY | 89.86% |
| 2017 | 318.02 Million CNY | 62.14% |
| 2016 | 196.14 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 205.58 Million CNY | -40.64% |
| 2024 Q2 | 211.05 Million CNY | 2.66% |
| 2024 Q3 | 220.64 Million CNY | 4.54% |
| 2023 FY | 1 Billion CNY | 14.71% |
| 2023 Q1 | 284.81 Million CNY | 33.27% |
| 2023 Q2 | 192.51 Million CNY | -32.4% |
| 2023 Q3 | 181.7 Million CNY | -5.62% |
| 2023 Q4 | 346.31 Million CNY | 90.59% |
| 2022 Q4 | 213.7 Million CNY | 9.51% |
| 2022 Q1 | 260.13 Million CNY | -6.5% |
| 2022 Q3 | 195.15 Million CNY | -5.94% |
| 2022 Q2 | 207.47 Million CNY | -20.24% |
| 2022 FY | 876.46 Million CNY | 8.38% |
| 2021 Q3 | 172.93 Million CNY | -4.81% |
| 2021 Q1 | 175.88 Million CNY | -13.8% |
| 2021 FY | 808.69 Million CNY | 12.62% |
| 2021 Q4 | 278.2 Million CNY | 60.88% |
| 2021 Q2 | 181.66 Million CNY | 3.29% |
| 2020 Q3 | 146.97 Million CNY | -27.17% |
| 2020 Q4 | 204.03 Million CNY | 38.83% |
| 2020 FY | 718.05 Million CNY | -11.26% |
| 2020 Q1 | 165.25 Million CNY | -38.28% |
| 2020 Q2 | 201.78 Million CNY | 22.1% |
| 2019 Q1 | 169.51 Million CNY | 0.0% |
| 2019 FY | 809.13 Million CNY | 34.0% |
| 2019 Q2 | 209.31 Million CNY | 23.48% |
| 2019 Q4 | 267.75 Million CNY | 64.72% |
| 2019 Q3 | 162.55 Million CNY | -22.34% |
| 2018 FY | 603.81 Million CNY | 89.86% |
| 2017 FY | 318.02 Million CNY | 62.14% |
| 2016 FY | 196.14 Million CNY | 0.0% |